Streetbeat News

Products Services

ENPH

Enphase Energy, Inc. (NASDAQ:ENPH) has started shipping its most powerful microinverters, the IQ8P, in Brazil, designed to support high-powered solar modules with a peak output of 480 W. The launch follows the introduction of the Solargraf platform in Brazil, aiding solar installers in the sales and installation process. The IQ8P Microinverters can handle a continuous DC current of 14 Amperes and pair with solar modules up to 670 W DC. They come with a 25-year limited warranty and integrate with the Enphase Energy System and IQ Gateway for easy monitoring and updates via the Enphase App.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 1:13 pm

RPRX

TEVA

Teva Pharmaceutical Industries Ltd. and Royalty Pharma have announced a collaboration to accelerate the development of Olanzapine LAI, a long-acting injectable for schizophrenia treatment. Royalty Pharma will provide up to $125 million in R&D funding support for the program.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 1:12 pm

MBRX

Moleculin Biotech, Inc. has provided a preliminary update on its recent clinical activities and outlined expected near-term milestones for its clinical development pipeline. The update includes progress on various clinical trials and anticipated key events that could influence the company's future direction and investor sentiment.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 1:06 pm

ALGS

Aligos Therapeutics presented clinical and nonclinical data at the AASLD Liver Meeting 2023, showing that its drug ALG-055009 has a favorable risk-benefit profile. This could potentially impact the company's stock as investors react to the positive news regarding the drug's development.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 1:05 pm

DXR

Daxor Corporation has announced the presentation of data from a Phase I NIH-sponsored trial at the American Heart Association Annual Meeting. The data is likely to be significant for the company's profile in the medical community and could influence investor perception.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 1:03 pm

IPA

ImmunoPrecise's subsidiary BioStrand has published a preprint of its white paper on Biorxiv.org, titled 'New Paradigm For Biological Sequence Retrieval Inspired By Natural Language Processing And Database Research'.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 1:01 pm

MDGS

Medigus' subsidiary, Metagramm, is set to develop Bubbl, an AI-powered writing and grammar tool. This move signals Medigus' entry into the AI-driven content creation market, potentially expanding its product offerings and market reach.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 12:56 pm

COST

LQR House has partnered with Cabal Tequila for a marketing and awareness campaign, which could lead to COSTCO shelf placement in California through their partnership with Alpha Distro.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 12:38 pm

ALZN

Alzamend Neuro has indicated to Benzinga that the safety aspects of its AL001 development could be eligible for a 505(b)(2) New Drug Application (NDA) pathway with the FDA, which may streamline the approval process.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 12:31 pm

ALZN

Alzamend Neuro has submitted an IND application for a Phase IIA clinical trial for its drug candidate AL001, aimed at treating Post-Traumatic Stress Disorder (PTSD). This submission marks a significant step for the company in the development of next-generation lithium therapeutics.

Portfolio Pulse from Benzinga Newsdesk

November 13, 2023 | 12:30 pm